MAPT and Alzheimer disease: Selenate treatment did not affect total tau protein expression level or phosphorylation levels of tau at pS404 and pT231, but reduced phosphorylation of tau at pS422 and pS396 (Fig. 6), which is consistent with previous reports in several other AD models [12], [13].